Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination With Epirubicin in Patients With Advanced Melanoma
18 Years
N/A
Both
Melanoma (Skin)
Trial Information
Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination With Epirubicin in Patients With Advanced Melanoma
OBJECTIVES:
Primary
- To estimate the non-comparative efficacy of sulindac and epirubicin hydrochloride in
patients with metastatic malignant melanoma.
Secondary
- To characterize the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral sulindac 2 hours prior to receiving epirubicin hydrochloride IV over
15 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease
progression or unacceptable toxicity.
Previously collected tumor blocks are assessed for cancer resistance markers by IHC.
After completion of study treatment, patients are followed for 1 month, and then every 3
months thereafter.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed malignant melanoma
- Metastatic disease
- Tumor block available for resistance marker analysis
- Measurable or evaluable disease
- No active brain metastases except for patients who have undergone successful complete
excision of solitary brain metastasis
PATIENT CHARACTERISTICS:
- Karnofsky performance status 80-100%
- ANC > 1 x 10^9/L
- Platelet count > 100 x 10^9/L
- Hemoglobin > 9 g/dL
- Serum bilirubin normal (except in patients with benign congenital hyperbilirubinemia)
- Not pregnant or nursing
- Negative pregnancy test
- Normal cardiac ejection fraction, cardiac wall motion, and ECG
- No active heart disease, including any of the following:
- Myocardial infarction within the past year
- Pericarditis
- Existing hypertension requiring treatment
- No other active serious medical or psychiatric disease
- No prior or concurrent malignancy, other than basal cell carcinoma of the skin , or
carcinoma in-situ of the cervix
PRIOR CONCURRENT THERAPY:
- No prior anthracycline or anthracenedione-containing chemotherapy regimen
- No prior cardiac radiotherapy
- No major surgery within the past 2 weeks
- No participation in any clinical trial within the past 4 weeks
- No other concurrent anticancer therapies
- Concurrent bisphosphonates allowed in patients with bony metastases with
extra-osseous measurable or evaluable lesions
- No other concurrent experimental medications
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To estimate the non-comparative efficacy of this treatment combination in patients with malignant melanoma. Response will be assessed using the RECIST Criteria
Outcome Description:
The interim analysis will study the objective response to treatment in the first cohort of 29 patients. Response will be assessed according to NCI -Response Evaluation Criteria in Solid Tumors (RECIST) guidelines
Outcome Time Frame:
Ongoing throughout trial
Safety Issue:
No
Principal Investigator
John Crown, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
St. Vincent's University Hospital
Authority:
Ieland: Irish Medicines Board
Study ID:
CDR0000613992
NCT ID:
NCT00755976
Start Date:
August 2007
Completion Date:
May 2010
Related Keywords:
- Melanoma (Skin)
- stage IV melanoma
- Melanoma
Name | Location |
|---|
